Skip to main content

Table 1 Demographic characteristic of CML patients responsive and non-responsive to imatinib therapy and blood donors

From: Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response

Characteristic

Imatinib Responsive Group (n = 30)

Imatinib Non-Responsive Group (n = 28)

Control Group (n = 28)

Ethnicity:

 Malays

13 (43%)

16 (57%)

15 (53%)

 Chinese

12 (40%)

7 (25%)

10 (36%)

 Indians

5 (17%)

5 (18%)

3 (11%)

Gender:

 Male

17 (57%)

13 (46%)

22 (79%)

 Female

13 (43%)

15 (54%)

6 (21%)

Age (year):

 18 - < 45

13 (43%)

11 (39%)

22 (79%)

  ≥ 45

17 (57%)

17 (61%)

6 (21%)

Mean ± std. dev

48 ± 13

46 ± 14

36 ± 9